Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceuticals"
DOI: 10.3390/ph14030247
Abstract: We herein report the development and evaluation of a novel HER2-targeting antibody–drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). In vitro and in… read more here.
Keywords: drug; antibody drug; linker platform; drug linker ... See more keywords